Cipla launches Yurpeak® (tirzepatide) for the treatment of Obesity and Type 2 Diabetes

Cipla Limited (BSE: 500087; NSE: CIPLA; and hereafter referred to as "Cipla") today announced the launch of Yurpeak® (tirzepatide), a one-weekly injectable therapy for managing obesity and type 2 diabetes mellitus (T2DM) - two of the country's most pressing health challenges. Cipla has the rights to distribute and promote Yurpeak® - the second brand of Lilly's tirzepatide in India, after Lilly received DCGI approval.

Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicated as an adjunct to diet and exercise for the treatment of Type 2 diabetes and Chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity.

Yurpeak® will be available on prescription in the KwikPen® device format in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, allowing for precise, convenient, and patient-friendly dosing.

Commenting on the launch, Achin Gupta, Global Chief Operating Officer, Cipla Limited, said: "The launch of Yurpeak® marks a transformative moment in the fight against obesity and type 2 diabetes mellitus, two of India's chronic conditions with a heavy burden. Cipla is entering this space with the same depth of expertise and scientific commitment that define our leadership in chronic diseases and in respiratory care. Our focus remains on accelerating access to globally benchmarked, future-ready therapies through collaborations like ours with Lilly, which bring together innovation, purpose, and scale to ensure advanced care reaches patients wherever they are."

Launch of Yurpeak® in India will help expand access to tirzepatide so that more patients can benefit from this innovative therapy. Cipla's strategic priority is to make it available across India, including regions beyond metro cities, leveraging its strong distribution network and deep market insights to drive greater nationwide reach and accessibility. Lilly will manufacture and supply Yurpeak® to Cipla, and the price will be the same as Mounjaro®.

Cipla will complement the launch of Yurpeak® with comprehensive patient education and support programs, including guidance on dosing, self-administration, and safe, informed use of the therapy. These initiatives are designed to help patients navigate their treatment confidently and responsibly, in consultation with their healthcare professionals. This approach is backed by Cipla's long-standing commitment to evidence-based communication and responsible care, empowering individuals to make timely health decisions and adopt sustainable wellness practices.

Shares of Cipla Limited was last trading in BSE at Rs. 1490.70 as compared to the previous close of Rs. 1497.45. The total number of shares traded during the day was 23472 in over 2549 trades.

The stock hit an intraday high of Rs. 1502.00 and intraday low of 1487.00. The net turnover during the day was Rs. 35102471.00.

Source : Equity Bulls

Keywords

Cipla INE059A01026 Pharmaceuticals Yurpeak Tirzepatide Type2DiabetesMellitus